Proximal versus total gastrectomy for locally advanced Siewert type II–III gastroesophageal junction cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, prospective, randomized parallel trial comparing proximal gastrectomy and total gastrectomy with D2 lymphadenectomy in operable patients with locally advanced Siewert type II–III gastroesophageal junction cancer. Eligible patients are randomized to either procedure, which may be performed open, laparoscopically, or robotically according to surgeon judgment. The primary outcome is 3-year disease-free survival, with secondary outcomes including postoperative mortality, complications, and number of metastatic lymph nodes retrieved. Participants are followed for up to five years to capture long-term oncologic outcomes and perioperative morbidity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age between 18 and 90 years
* Histologically confirmed locally advanced Siewert type II-III gastroesophageal junction cancer
* Considered operable after multidisciplinary tumor board evaluation
* Candidate for curative surgical resection with D2 lymphadenectomy
* Provision of written informed consent

Exclusion Criteria:

* Early-stage gastroesophageal junction cancer
* Gastric cancers located in the antrum or corpus
* Severe anesthetic risk (American Society of Anesthesiologists \[ASA\] class IV or higher)
* Pregnancy
* Patients unwilling or unable to provide informed consent

Where it's running

• Bakirkoy Dr. Sadi Konuk Training and Research Hospital
  Istanbul, Istanbul, Turkey (Türkiye) Recruiting

Study contacts

• Principal investigator: Turgut Donmez, MD — Bakirkoy Dr. Sadi Konuk Research and Training Hospital
• Study coordinator: Turgut Donmez, MD
• Email: surgeont73@hotmail.com
• Phone: +90 5347400967

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LY4337713 for people with FAP-positive ovarian, breast, pancreatic, colorectal, or esophageal cancers

  This trial tests LY4337713, a FAP-targeted lutetium-177 therapy, in people with advanced cancers that show high levels of fibroblast activation protein (FAP).

  Recruiting at 17 sites Phase 1 Eli Lilly and Company · Newport Beach, California and 29 other locations · NCT07213791

• LY4257496 for GRPR-positive advanced breast, colorectal, prostate, and endometrial cancer (OMNIRAY)

  This Phase 1 test tries LY4257496, with GRPR imaging using LY4257529 and sometimes standard treatments, to see if it is safe and helps people with GRPR-positive advanced breast, colorectal, prostate, or endometrial cancer.

  Recruiting at 15 sites Phase 1 Eli Lilly and Company · Duarte, California and 32 other locations · NCT07114601

• High-sensitivity blood test to detect and monitor multiple cancers

  This study will test a high-sensitivity blood test that looks for tumor DNA to detect and follow several common cancers in adults with those cancers or people having routine health screenings.

  Recruiting Yonsei University · Seoul · NCT07035587

• Evaluating HTL0039732 for Advanced Solid Tumours

  This study is testing a new drug called HTL0039732, alone and with another treatment, to see if it can help people with advanced solid tumors by boosting their immune response against cancer.

  Recruiting at 6 sites Phase 1/2 Cancer Research UK · Cambridge and 5 other locations · NCT05944237

• Candonilimab with Fruquintinib and Paclitaxel Albumin-Bound as second-line treatment for advanced gastric cancer

  This phase 2 trial tests whether adding candonilimab to fruquintinib and nab-paclitaxel helps people with advanced gastric or gastroesophageal junction cancer who progressed after first-line therapy.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07920224

• TEAS after gastrectomy to aid recovery after laparoscopic stomach cancer surgery

  A randomized trial tests whether transcutaneous electrical acupoint stimulation (TEAS) after laparoscopic gastrectomy helps people recover faster and with less pain compared with a sham treatment.

  Recruiting at 8 sites The Affiliated Hospital of Qingdao University · Qingdao, Shandong and 7 other locations · NCT07898293

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.